These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1205 related items for PubMed ID: 29498875

  • 1. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V, Bláha M, Lánská M, Havel E, Vyroubal P, Zadák Z, Žák P.
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [Abstract] [Full Text] [Related]

  • 2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V, Katsiki N, Makrygiannis S, Mavrogieni S, Karampetsou N, Manolis A, Melidonis A, Mikhailidis DP, Kolovou GD.
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [Abstract] [Full Text] [Related]

  • 3. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T.
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [Abstract] [Full Text] [Related]

  • 4. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA, Elshourbagy NA, Mousa SA.
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [Abstract] [Full Text] [Related]

  • 5. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 6. [Position of lipoprotein apheresis in present].
    Bláha V, Bláha M, Lánská M, Havel E, Vyroubal P, Zadák Z, Vrablík M, Piťha J, Žák P, Sobotka L.
    Vnitr Lek; 2015 Nov; 61(11):958-64. PubMed ID: 26652784
    [Abstract] [Full Text] [Related]

  • 7. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
    Spitthöver R, Röseler T, Julius U, Heigl F, Schettler VJJ, Kühn R, Leebmann J, Raabe A, Knittel M, Schürfeld C, Moesenthin M, Bernhardt WM, Röseler E, Ketteler M, Heibges A, Klingel R.
    J Clin Apher; 2019 Aug; 34(4):423-433. PubMed ID: 30817043
    [Abstract] [Full Text] [Related]

  • 8. PCSK9 inhibition in the management of familial hypercholesterolemia.
    Ogura M.
    J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ, Muellendorff F, Schettler E, Platzer C, Norkauer S, Julius U, Neumann CL.
    Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA, Nohara A, Higashikata T, Tada H, Nakanishi C, Okada H, Konno T, Sakata K, Hayashi K, Inazu A, Mabuchi H, Yamagishi M.
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA.
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [Abstract] [Full Text] [Related]

  • 14. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT, Enebakk T, Thunhaug H, Hovland A.
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [Abstract] [Full Text] [Related]

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 16. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R, Štulc T, Votavová L, Schwarzová L, Vaclová M, Freiberger T.
    Vnitr Lek; 2016 Oct; 62(11):887-894. PubMed ID: 28128575
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K.
    JAMA; 2016 Aug 16; 316(7):743-53. PubMed ID: 27533159
    [Abstract] [Full Text] [Related]

  • 18. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B, Gaciong Z, Hoffman P, Jankowski P, Kłosiewicz-Latoszek L, Kaźmierczak J, Mitręga K, Opolski G, Pająk A, Ponikowski P, Rynkiewicz A, Stępińska J, Średniawa B, Kalarus Z.
    Kardiol Pol; 2016 Aug 16; 74(4):394-8. PubMed ID: 27098076
    [Abstract] [Full Text] [Related]

  • 19. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K.
    Curr Pharm Des; 2017 Aug 16; 23(10):1495-1499. PubMed ID: 28155622
    [Abstract] [Full Text] [Related]

  • 20. Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
    Papademetriou V, Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Dimitriadis K, Tsioufis K.
    Curr Pharm Des; 2018 Aug 16; 24(31):3647-3653. PubMed ID: 30317985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.